Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for women and men with HR+/ERBB2-negative early breast cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ribociclib-shows-lasting-benefit-early-breast-cancer-2025a1000pol?src=rss
Author :
Publish date : 2025-09-25 15:05:00
Copyright for syndicated content belongs to the linked Source.
